What’s happening at InnoCore?

We’re thrilled to announce that InnoCore has been awarded a Just Transition Fund (JTF) to develop a peptide microsphere long-acting injectable. This milestone underscores the innovation and impact of our sustained-release platform in metabolic health. Stay tuned as we accelerate toward transformative solutions in peptide delivery.

InnoCore Pharmaceuticals today initiated a new formulation development program focused on a specific small molecule drug substance, reinforcing its long-standing commitment to supporting its customers across a range of molecules.

InnoCore attended and presented at the PODD: Partnership Opportunities in Drug Delivery Conference, taking place between 27–28 October 2025 in Boston, MA.

InnoCore Pharmaceuticals today announced a project extension with an existing European biotech partner focused on developing a long-acting injectable protein formulation using its proprietary SynBiosys® technology.

InnoCore Pharmaceuticals today announced a new formulation development contract with a returning Top 10 global pharmaceutical company. The new agreement builds on the success of earlier collaborations and further strengthens the long-standing relationship between the two companies.

Meet us at the BioEurope in Vienna from 3 - 5 November! Let’s build the future of Biologics and Peptides together.

Meet us at the CPHI to explore how our SynBiosys® platform is transforming the development of biodegradable long-acting injectables for peptides, proteins, and other biologics.

Join Rob Steendam, at his talk on “SynBiosys®: Long-Acting Injectable Microspheres and In Situ Forming Depots for Delivery of Peptides and Proteins”!

Join InnoCore at BioJapan! Let's partner to shape the future of peptides and biologics together.